Pharma / Biotech

Dolutegravir Maintains Virologic Suppression in Multiple Trials

Dolutegravir-based regimens provide long-term suppression in HIV patients, according to presentations at the 22nd International AIDS Conference in Amsterdam.

Source link




Related posts

PHENYLEPHRINE HYDROCHLORIDE Injection [Amneal Biosciences LLC]

Newsemia

OSMOLEX ER (Amantadine) Tablet, Extended Release [Vertical Pharmaceuticals, LLC]

Newsemia

FDA Approves Opdivo as Third-Line Rx for SCLC

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy